Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChangHER-SC: Preference for SC vs IV Trastuzumab in HER2+ Advanced Breast Cancer
NCT01875367Phase 3Completed
- Sponsor
- GEICAM
- Start
- Sep 2013
- Primary completion
- Nov 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by GEICAM. Started Sep 2013; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01875367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01875367.